What is the rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations?

What is the rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations?

What is the clinical rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations over time?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Janice Tsang, MBBS, MRCP(UK), FRCP (Lond.)

Specialist in Medical Oncology
Hon. Clinical Assistant Professor
Li Ka Sing Faculty of Medicine
The University of Hong Kong